

#### **Abstract**

Cost-effective, noninvasive screening methods for preclinical Alzheimer's disease (AD) and

- other neurocognitive disorders remain an unmet need. The olfactory neural circuits develop AD
- pathological changes prior to symptom onset. To probe these vulnerable circuits, we developed
- the digital remote AROMHA Brain Health Test (ABHT), an at-home odor identification,
- discrimination, memory, and intensity assessment.
- The ABHT was self-administered among cognitively normal (CN) English and Spanish speakers
- 30  $(n=127)$ , participants with subjective cognitive complaints (SCC; n=34), and mild cognitive
- impairment (MCI; n=19). Self-administered tests took place remotely at home under unobserved
- (among interested CN participants) and observed modalities (CN, SCC, and MCI), as well as in-
- person with a research assistant present (CN, SCC, and MCI).
- Olfactory performance was similar across observed and unobserved remote self-administration and between English and Spanish speakers. Odor memory, identification, and discrimination scores decreased with age, and olfactory identification and discrimination were lower in the MCI group compared to CN and SCC groups, independent of age, sex, and education.
- The ABHT revealed age-related olfactory decline, and discriminated CN older adults from those with cognitive impairment. Replication of our results in other populations would support the use of the ABHT to identify and monitor individuals at risk for developing dementia.
- Keywords: Remote assessment, screening, Alzheimer's disease, Mild cognitive impairment, olfaction.
- 

### 44 **Introduction**

Alzheimer's disease (AD) affects over 6.9 million Americans, and this number is expected to grow to 13.9 million by 2060 with devastating economic consequences for society (>\$335B / year in the US) and families (>\$330B in unpaid care provided predominantly by  $\pm$  family members)<sup>1</sup>. The dementia syndrome of AD is now considered an advanced stage of the disease since radiological and pathological evidence demonstrate that pathology begins to 50 accumulate 15-20 years before the onset of memory symptoms<sup> $2-5$ </sup>. At the onset of self-reported memory symptoms, neuropsychological testing is often normal – a stage termed subjective 52 cognitive decline or subjective cognitive complaints  $(SCC)^6$ . As the disease progresses to amnestic memory deficits revealed by psychometric testing, this stage becomes mild cognitive impairment (MCI), a stage preceding dementia where activities of daily living are not impaired yet by cognitive deficits. While most clinical trials have focused on the symptomatic stage of the disease, many investigators hypothesize that treatment during these preclinical SCC and MCI 57 stages is likely to be more efficacious<sup> $7-9$ </sup>. A cost-effective, noninvasive screen for preclinical AD performed at home would enable important research in this area by affording a means for more efficient screening, such as blood-based biomarkers and imaging, for eligibility criteria for 60 clinical trials targeting preclinical or early-stage disease  $10^{-12}$ .

61

62 The measurement of early olfactory impairment is a prime candidate as a component of an early 63 detection assessment<sup>13</sup>. Many brain regions process olfactory input from primary olfactory 64 neurons<sup>14–16</sup>, and these regions are damaged early in the disease – with both the olfactory bulb 65 and entorhinal cortex among the first sites of tau pathology<sup>17</sup>. The amygdala and piriform





While olfaction has been suggested as a potential screening tool for AD, logistical challenges 95 and questions of specificity have hindered its widespread adoption<sup>43,60,61</sup>. To address these limitations, we developed a battery of olfactory tests. This battery includes an odor percept identification (OPID) test, where participants smell an odor, answer a question, and then choose from four provided odor names. The battery also includes a percepts of odor episodic memory (POEM) test, where participants distinguish between new odors and those presented earlier; and an odor discrimination (OD) test, where participants identify pairs of smells as either the same or different. This battery was administered using an olfactometer to deliver odors in earlier work, 102 and we demonstrated selective odor memory loss in participants at risk of developing MCI<sup>43</sup>. In response to the urgency of the COVID pandemic and the respiratory transmission of the SARS-CoV2 virus, our team moved to the use of one-time use labels with embedded odors and 105 developed an abbreviated COVID Smell Test<sup>62</sup> as an early at-home screen for SARS-CoV2 infection. Subsequent testing using one-time odor labels in both English and Spanish in 30 states 107 and Puerto Rico<sup>63</sup>, as well as in Argentina (manuscript in preparation), provided valuable pilot data that allowed us to adapt our olfactory battery into a bilingual at-home self-administered brain health test to screen for both nasal and cognitive deficits in processing olfactory deficits.



ABHT adds a meta-cognition measure embedded in the odor percept identification tasks. Participants were instructed by the web-based app to sample the odor, and then choose an odor name from a forced choice list of 4 options. They are then asked to evaluate their confidence in each odor identification decision with a scale that includes the following options: "I Guessed," "I Narrowed Down to Three," "I Narrowed Down to Two," or "I Am Certain.". This confidence metric is quantified for the OPID9 and OPID18 odor identification tests as the number answered correct among items paired with the "I am Certain", "I Narrowed Down to Three", and "I Narrowed Down to Two" responses (OPID9noguess, OPID18noguess scores). Three sets of bilingual (English / Spanish) cards, which are arrayed with odor labels, were designed to administer the OPID9 odor percept identification and odor intensity test (Part 1, Card A), the OPID18 odor percept identification and POEM memory test (Part 2, Cards B and C), and 145 the OD10 odor discrimination test (Part 3, Cards D and E) (Figure 1). Numerous concentrations of each odor were packaged in different labels, and perceptions of odor intensity using a 10-point Likert scale that ranges from 0 (no odor) to 10 (strongest odor imaginable) were obtained from healthy college-aged participants in pilot studies. The final label-embedded odorant concentrations were selected with a mean perceived intensity of 7-7.5. To ensure that the headspace for each label was not contaminated by one or more components of the adhesive to hold the labels together, we performed gas chromatography / mass spectrometry for each odor label (Extended Data Figure 1). We did not find a common component in the headspace of all labels, which could confound olfactory performance.



**Figure 1. AROMHA Brain Health Test Schematic.** Following online prescreening, online consent, the web-based program instructs you through the 5 bilingual (English / Spanish) cards (A). Card A is comprised of a practice odor P followed by the 9 odor labels comprising the OPID9 test. Adjacent in the blue box (B) is the workflow for these tests as directed by 159 the testyourbrainhealth.com software to generate the OPID9, OPID9noguess, and average intensity scores. After a 10-minute break, participants are instructed to work through Cards B and C using the workflow in the green box (B) to generate the POEM, OPID18, and OPID18noguess scores. Then participants are instructed to move on to Cards D and E using the workflow in the purple box (B) to generate an OD10 odor discrimination score.









205 **Table 1. Demographic information and olfactory function in cognitively normal** 

206 **participants who underwent observed and unobserved self-administration conditions of the** 

207 **AROMHA Brain Health Test.** Values are means (SD). T-tests were performed across groups

208 for age, education, olfactory scores, and test duration. Chi-square test was performed on sex and

209 speaking-language proportions across groups. **Bold** indicates a statistically significant difference

210 that remained significant after Bonferroni correction.

211

### 212 **Validation of the AROMHA Brain Health Test in Anosmic patients.**

213 Table 2 displays the demographics and olfactory scores of 7 patients with anosmia recruited from 214 a smell loss clinic and CN participants. As expected, the anosmic group performed significantly

215 worse on every olfactory metric  $(p < .001)$  in our battery, as compared to the CN group although

216 they did not take significantly longer to complete the battery when grouped across various

217 modalities (Extended Data Table 3). The anosmic group did not perform statistically different

218 from chance performance on every olfactory measure, which was not the case for the CN control

219 group.

220



#### 221 **Table 2. Distribution of olfactory scores of anosmic patients and CN participants on the**

222 **AROMHA Brain Health Test.** The first column lists the score following random selection of

223 the answers for each test, e.g., the participant had no olfactory information to guide selection of

224 the answers. Values are means  $(SD)$ . NA = not applicable. Wilcoxon signed-rank tests were

225 performed across groups for age, education, olfactory scores, and test duration. The chi-square

226 test was performed for sex. **Bold** indicates a statistically significant difference that remained

227 significant after Bonferroni correction.

228

## 229 **Equivalence of the AROMHA Brain Health Test in English vs. Spanish-speaking**

## 230 **Cognitively Normal Participants**

231 When assessing the potential effect of language, no significant differences were found across

232 olfactory scores between cognitively normal English-speaking and Spanish-speaking

233 participants. Demographically only age was significantly different, as the English-speaking

234 group was significantly older than the Spanish-speaking group  $(p = .001)$  (Table 3).

235



236 **Table 3. Demographic information and olfactory function in cognitively normal English-**

237 **speaking and Spanish-speaking participants.** Values are means (SD). T-tests were performed

238 across groups for age, education, clinical variables, olfactory scores, and test duration. Chi-

square test was performed on sex and speaking-language proportions across groups. **Bold**

indicates a statistically significant difference that remained significant after Bonferroni

- correction.
- 

# **Diminished Olfactory Measures in the AROMHA Brain Health Test with increasing age**

- When assessing the effect of age on olfaction, linear regression models of olfactory scores as a
- function of age of the CN participants showed that greater age was significantly associated with
- 246 lower OPID9noguess ( $\beta$  = -0.02,  $p$  = .002), OPID18 ( $\beta$  = -0.04,  $p$  < .001), lower OPID18noguess
- 247 ( $\beta$  = -0.06, *p* < .001), lower OD10 ( $\beta$  = -0.02, *p* < .001), and lower POEM ( $\beta$  = -0.004, *p* < .001)
- 248 scores, while the association with OPID9 ( $\beta$  = -0.01,  $p$  = .01) and average intensity ( $\beta$  = -0.007,  $p$
- = .28) scores did not reach significance after Bonferroni correction (Figure 2).





scores, while the association with (a) OPID9 (β = -0.01, SE = 0.005 p = .01, adj.  $R^2$  = .04) and



259

# 260 **Performance of AROMHA Brain Health Test Distinguishes Participants Aged +55 who are**

### 261 **Cognitively Normal, with Subjective Cognitive Concerns or with Mild Cognitive**

- 262 **Impairment.**
- 263 The sex and education of participants across the CN, SCC, and MCI groups were not
- 264 significantly different after Bonferroni correction. Participants in the MCI group were, as
- 265 expected, older than those in the CN group  $(p=0.01)$ . Comparisons of each olfactory score of the
- 266 ABHT for participants who are CN, have SCC, or have MCI reveal significant olfactory
- 267 differences between subgroups, other than in the OD10, POEM odor memory score, and
- 268 evaluations of average odor intensity (Table 4). Comparisons across cognitive groups in this +55
- 269 sample revealed no demographic differences in sex and education, or in the test duration time.
- 270



271 **Table 4. Olfactory function across cognitive status among participants aged 55+.** Values are

272 means (SD). T-tests were performed across groups for age, education, clinical variables,



- 274 groups. **Bold** indicates a statistically significant difference that remained significant after
- 275 Bonferroni correction for 21 comparisons (*p* < .002).
- 276
- 277 When assessing the effect of cognitive status group on olfactory test components, ANCOVAs
- 278 revealed a significant effect on OPID9, OPID9noguess, OPID18, OPID18noguess, and OD10
- 279 scores (Table 5). No effects of cognitive status group were found for the POEM or average
- 280 intensity scores. After Bonferroni correction for 21 comparisons ( $p < .002$ ), post-hoc pairwise
- 281 comparisons revealed significantly lower scores in the MCI group compared to CN older adults
- 282 for the OPID9, OPID18, OPID18noguess, OD10 and to the SCC group for the OPID18 and
- 283 OPID9 scores.
- 284
- 285 Interaction effects were found with age for the OPID9noguess, OPID18 no guess scores, and
- 286 OD10, however they did not remain significant after Bonferroni correction for 7 comparisons (p
- 287 < .007). Other olfactory components did not interact with age (*p* > .05). No interaction effect

288 with sex or education were found with any olfactory scores  $(p > .05)$  (Table 4).

289







## 290 **Table 5. ANCOVA models comparing different olfactory scores across groups.** DF =

291 Degrees of Freedom, F = F-statistic, p = p-value,  $np^2$  = partial Eta squared. CI = Confidence

292 interval. **Bold** represents post-hoc *p* values that remained significant after Bonferroni correction

293 for 21 comparisons  $(p < .002)$ .

294  $\alpha$ <sup>*p*</sup> values from pairwise post-hoc comparisons adjusted for age, sex, and education.

295

# 296 **Discussion**

297

298 In this study, we tested and validated a self-administered olfactory test battery on cognitively

- 299 healthy English and Spanish-speaking cohort in the home setting, under observed and
- 300 unobserved self-administered conditions. We began with observed self-administered testing of

participants who were cognitively normal, had expressed subjective cognitive concerns (SCC), and had a diagnosis of Mild Cognitive Impairment (MCI). Both participants with SCC and MCI 303 are at risk of developing Alzheimer's disease dementia<sup>66,67</sup>. The majority of this observed testing was completed with the convenience of a remote in-home setting, using Zoom to share the testing screen and a video of the participant with a research assistant observing the workflow, noting challenges, and being available if questions or concerns arose. Some of the participants chose to self-administer the test without the Zoom interface and with a research assistant in the room for questions because they preferred this or found it more convenient. After about three months of observed and largely remote self-administered testing across the spectrum of cognitive impairment (from CN to MCI), we shifted to a completely unobserved remote testing option for any cognitively normal participants who felt comfortable engaging with the test entirely on their own. When given the option to self-administer the test remotely, independent of a research assistant, the majority of cognitively healthy participants, representing a wide age spectrum ranging from 20 to 92 years old, chose unobserved self-administration.

We found equivalent olfactory performance when comparing observed and unobserved self-administration of the ABHT among CN participants in unadjusted analyses, other than shorter test duration and a younger population on average in the observed setting. We also validated the test on an anosmic subsample, demonstrating that anosmic patients performed as expected at chance level for each olfactory test. When comparing the olfactory battery scores between languages, no differences were found regarding olfactory subtest scores between CN English and Spanish-speaking populations in unadjusted analyses. We also found that lower odor percept



populations of interest. This included protocols for online screening for eligibility, online

consenting, and an optimized remote user interface to guide participants through various

olfactory tasks. We also modified odor delivery by using odor labels on mailable cards. Unlike

341 our COVID test<sup>62,63</sup>, the ABHT is particularly targeted for participants aged 55+, a population

- generally less familiar with fully online test administration. We enrolled participants as old as 88
- in the CN and SCC groups and 95 in the MCI group, who were able to successfully self-
- administer the test and enter responses on the web-based platform. The remote administration

paradigm afforded participation from 21 different US states and Puerto Rico through online recruitment via an MGH and clinicaltrials.gov websites. The robust engagement of older participants in entirely independent, unobserved testing—yielding olfactory performance outcomes statistically indistinguishable from those obtained in observed settings—constitutes a significant finding. This challenges the prevailing assumption that older individuals are either unable or unwilling to effectively engage in self-administered remote screening methods such as ours. This screen was designed to address the unmet need of early detection of biomarkers in participants who are CN and those who have SCC but may not meet testing thresholds for MCI. We recruited patients with MCI to validate the efficacy of this screen to detect differences in our olfactory tests under conditions of more apparent cognitive impairment, as we and others 356 previously demonstrated<sup>40,43,60,70</sup>. Each olfactory identification score from the ABHT, including the 9-item sub scores (i.e., OPID9, OPID9 no guess), was lower in the MCI group compared to CN aged +55 groups. This result indicates that the ABHT could be used as a marker of cognitive decline in older adults and replicates the findings of two meta-analyses that demonstrated a specific pattern of olfactory impairment targeting more severely olfactory identification in 361 patients with Alzheimer's disease dementia<sup>52</sup> and MCI<sup>70</sup>. This early decline in odor identification likely reflects damage in specific limbic and medial temporal lobe olfactory areas involved in olfactory identification in the earliest stages of AD (i.e., piriform cortex, amygdala, entorhinal 364 cortex, hippocampus)<sup>20,21,31–37,71,72</sup>. At the cognitive level, olfactory identification tasks are 365 associated with declarative memory<sup>38,73</sup> and are predictive of cognitive decline in CN older 366 adults<sup>44–49</sup> and of the conversion to MCI<sup>42,50,51</sup>. Future studies should aim to replicate these

367 findings and assess the predictive value of the ABHT and odor percept identification sub-scores 368 on AD biomarkers and longitudinal cognitive decline in CN older adults.

369

370 Olfactory discrimination (OD10) was also lower in the MCI group compared to CN aged 55+ 371 group. This result replicates and is aligned with the results of previous studies showing a lower 372 olfactory discrimination performance in  $MCI<sup>54</sup>$  and predictive value of olfactory discrimination 373 in further cognitive decline<sup>48</sup>. Unlike the basic detection of odors, both identification and 374 discrimination of odors require high-level cognitive functions such as working memory and 375 decision making, which could explain our results<sup>54</sup>. The hippocampal network is also associated 376 with olfactory discrimination<sup>74</sup>, early damages to this structure in AD could explain these 377 findings. Future studies should investigate the relationship between hippocampal damage and 378 olfactory discrimination tasks in participants at risk of AD using volumetric magnetic resonance 379 imaging and tau  $\text{PET}^{18}$ .

380

Objective measurements of olfactory identification, discrimination, and memory were negatively associated with age in the asymptomatic CN sample. These results are not surprising and replicate the robust literature on the effect of normal aging on olfactory function. Indeed, according to a meta-analysis including 175,073 participants (18-101 years), olfactory impairment would be prevalent at 34.5% in studies with a mean age above 55 years, while the prevalence 386 would be at 7.5% in studies with a mean age below 55 years<sup>75</sup>. The decline starts in the fifth 387 decade of life<sup>76</sup> and is general across different olfactory capacities such as olfactory detection, 388 discrimination, identification<sup>77</sup>, and memory<sup>78,79</sup>. Our results indicate that perceived olfactory



Having validated remote unobserved self-administration in CN people and demonstrated that remote observed self-administration of the ABHT is feasible in an MCI population (95% of MCI participants completed testing in this mode), and by finding expected differences in olfactory identification scores as shown in previous studies, we are poised to begin studies in deeply phenotyped populations to quantify the predictive value of ABHT outcomes on biomarkers of neurodegenerative disease, including Alzheimer's, Lewy Body disease, and concussive and non-concussive head trauma. These studies can incorporate both English and Spanish-speaking participants, as we did not find any differences in olfactory scores among the CN English and Spanish-speaking participants. Different olfactory-behavioral profiles are hypothesized to emerge depending on disease neuropathology, as different brain areas and networks of the 407 central olfactory system are associated with different olfactory tasks $83-85$ . While previous studies 408 showed that MCI and AD predominantly affect olfactory identification<sup>52,70</sup>, the olfactory bulb is affected at the earliest stage of Parkinson's disease resulting in a general olfactory impairment with reduced olfactory detection performance and leads to a decrease in various olfactory tasks

411 (e.g., discrimination of odors, identification of odors)<sup>52,86</sup>. Other conditions such as Lewy body 412 dementia<sup>87</sup>, frontotemporal dementia<sup>88</sup>, and exposure to head impacts and traumatic brain 413 injury<sup>89–91</sup> can also cause olfactory impairments.

414

415 When combined with other digital biomarkers, a mobile self-administrated and diverse smell 416 assessment like ours could accelerate screening for neurodegenerative diseases in asymptomatic 417 or newly symptomatic individuals who would benefit from more definitive subsequent tests $^{92,93}$ , 418 such as blood-based, image-based, or cerebrospinal fluid (CSF)-based diagnostics, especially in 419 individuals presenting additional risk factors for dementia such as subjective cognitive decline<sup>66</sup>. 420 depression<sup>94</sup>, and genetic risks factors such as the APOE-4 allele<sup>95</sup>. Home-based tests also have 421 the potential to enhance the involvement of underrepresented groups in research settings<sup>96</sup> and to 422 save time and cost of transportation, to save costs for the healthcare system, and to increase 423 . patient satisfaction<sup>97,98</sup>.

424

This study has certain limitations. The main limit is the restricted availability of neuropsychological testing for a proportion of the participants (unverified vs verified) in the sample. Additionally, the results of this study correlate with a robust body of literature, and demonstrate its utility in real-world settings. Future longitudinal studies will assess the predictive value of the ABHT on longitudinal cognitive decline and highlight the utility of this olfactory battery in mapping correlations between patterns olfactory decline and the progression of various neurodegenerative diseases. While not a limitation in this preliminary validation of the

AROMHA Brain Health Test, biomarker availability will be an essential component in future studies that assess the predictive power that this noninvasive preliminary screen may hold. **Conclusion**  The ABHT is a novel remote olfactory battery that exhibited similar performance across observed and unobserved self-administration among CN participants as well as among English and Spanish-speaking CN participants, while anosmic patients performed at chance level as expected. Odor percept identification, discrimination, and memory subtests were sensitive to the aging effect on the olfactory system. Each olfactory identification subtest, including the short 9-

item version, and the olfactory discrimination subtest showed lower performance in the MCI

group, mirroring results in the literature. These results suggest that the ABHT could be used in

clinical research settings in different languages to explore the utility of olfactory biomarkers to

predict the presence of blood-based, image-based, or cerebrospinal fluid (CSF)-based biomarkers

of neurodegenerative disease and longitudinal development of clinical symptoms.

**Methods**

**Development and Quality Control of the AROMHA Brain Health Test**

The ABHT was updated for remote at-home self-administration of previously developed Odor

Percept Identification (OPID), Percepts of Odor Episodic Memory (POEM), and Odor

453 Discrimination (OD) subtests<sup>43</sup>. All pre-screening, informed consent, and administration of the

test occurs online through a web-based interface (testyourbrainhealth.com). This updated version

of the test consisted of five different 8.5 " x 11" single-use cards that were packaged in one

envelope and mailed to the participant's home. We expanded the manufacturing of odor labels 457 from the three odors utilized in the COVID smell test<sup>62</sup> to include additional 15 odors. Odor 458 also labels were manufactured by MFR Samplings using Living Library<sup>TM</sup> odors purchased from 459 International Flavors and Fragrances  $(IFF)^{62}$ . Odors were presented to participants in a peel-and-sniff manner and contained proprietary naturalistic odors from the Living Library developed by IFF (https://www.iff.com/). Gas chromatography/mass spectrometry were conducted at the Mass Spectrometry core at the Bauer Laboratory in the Harvard Chemistry Department. Briefly, each odor label was completely opened in a stoppered 15 ml conical tube and allowed to reach equilibrium for 1 minute at room temperature. Then a Hamilton Syringe was used to inject a representative sample of the headspace into the GC/MS instrument. The peaks were normalized to 2-methyl-3-heptanone equivalents, and analyzed for common set of peaks that might represent a common contaminant from the adhesive. All samples were run the same day to eliminate batch effects (Extended Data Figure 1).

Participant responses to all components of the ABHT were collected on a web-based application at testyourbrainhealth.com designed for independent self-administration of the survey questions and the olfactory battery (Extended Data Figure 2). The data is stored on a HIPPA-compliant AWS server. The prescreening module and the informed consent module were developed on a RedCAP platform at the Massachusetts General Hospital. All protected health information was kept on RedCAP platform. Participants had the option to call a research assistant for live help in English or Spanish at any time during remote testing. The web-based AHBT application directed participants to a RedCap secure e-consent project to collect identifiers. Once consented, participants were sent back to the AROMHA, Inc. app to walk through all three parts of the

battery and collect olfactory information associated with their card ID. The app was designed to lead participants through every stage of testing, including directions on how to peel odor labels 481 and sample odors as well as respond to questions regarding odor intensity, odor identification  $\&$ naming confidence, odor memory, and odor discrimination. The application has the ability to run in an English or Spanish language mode, based on participant preference. During testing, it collects participant responses for all aspects of the olfactory battery in addition to the timing of those inputs. The app generates summary and item-specific data on these metrics that can be downloaded by researchers for analysis and joined offline to demographic information collected in RedCap following the e-consent process. These results are not shared with participants.

*Part 1: Odor Percept Identification Test (OPID9)*. Participants first completed the OPID9, which involved identifying nine distinct odors: menthol, clove, leather, strawberry, lilac, pineapple, smoke, soap, and grape. These odors were selected for their predictive value in identifying the conversion to Alzheimer's disease (AD) in patients with mild cognitive 493 impairment  $(MCI)^{39}$ . After each odor presentation, participants rated the intensity on a Likert scale from 0 to 10. Subsequently, they were presented with four odor names, asked to choose the label that best represented the odor they sampled, and asked to rate their confidence in their identification choice using the following scale: "I Guessed," "I Narrowed Down to Three," "I Narrowed Down to Two," or "I Am Certain." (Extended Data Figure 2B). This process was repeated for all nine odors. Following the completion of the OPID9 test, there was a 10-minute delay during which participants answered demographic, medical, nasal, and memory-related questions.

*Part 2: Percepts of Odor Episodic Memory (POEM) / OPID18*. After the 10-minute break, participants completed the POEM/OPID18 tests. These tests included the nine odors from Part 1 and nine additional odors: coffee, peach, chocolate, orange, dirt, banana, lemon, bubble gum, and rose. The odors were presented in a stereotyped random order that was held consistent across all participants. For each odor, participants first indicated whether the odor sampled was presented in Part 1 (yes/no), OPID9. As in the earlier odor identification test, they then selected the odor name most representative of the odor from four choices and rated their confidence in their selection.

*Part 3: Odor Discrimination (OD10)*. In Part 3, participants were presented with 10 pairs of odors, all of which were previously presented in Parts 1 and 2. They were asked to determine whether the paired odors were the same or different (yes/no).

The POEM index was calculated as the difference between the proportion of correct and incorrect recognitions, with scores ranging from -1 to 1. OPID9 and OPID18 scores were calculated as the total number of correctly identified odors, with maximum scores of 9 and 18, respectively. The OD10 score was the total number of correctly discriminated odor pairs, with a maximum score of 10. The average intensity score was derived from the mean intensity ratings of the nine odors from Part 1 on the Likert scale. OPID9noguess and OPID18noguess scores were calculated as the total number of odors identified correctly where the participant did not select "I Guessed" for the confidence question immediately following identification.







All analyses were conducted in R using *Base R, effectsize, emmeans, and rstatix* packages. Student T-tests were used to compare demographics and olfactory variables between observed and unobserved conditions and between English and Spanish-speaking groups, while the Wilcoxon signed-rank test was used to compare anosmic patients with CN participants. To assess



Gomez-Isla M.D., Ph.D., and Brad Hyman, M.D., Ph.D. for their assistance with recruiting

ADRC subjects.

BJ is supported by scholarships from the Canadian Institutes of Health Research, the Fonds de Recherche Québec Santé, the Quebec Bio-Imaging Network, the Université du Québec à Trois-Rivières, and MITACS. The study was funded by NIH R41AG062130 and NIHR42AG 062130 (awarded to S.R.), and U01DC019579 (awarded to M.W.A.).

#### 611

# 612 **Author Contributions**

- 613 S.R., A.D.A., and M.W.A. conceptualized and designed the study. B.J., C.M., D.D., A.R.,
- 614 A.A.S., B.E., acquired and analyzed data. B.J., C.M., A.R., A.D.A., and M.W.A. drafted text and
- 615 prepared figures. All authors revised content.
- 616

617 **Competing interests** 

- 618
- 619 S.R. and M.W.A. are co-founders and own shares in Aromha, Inc. C.M. and A.D.A. are
- 620 consultants for Aromha, Inc. M.W.A. and A.D.A.'s participation in this research was reviewed
- 621 by the MGB Office of Industrial Interactions. M.W.A is a consultant for Sudo Bioscience
- 622 Limited, Transposon Therapeutics, and has received in kind donations from IFF and from Eli
- 623 Lilly. He has received speaking fees from Biohaven and Incyte.
- 624

# 625 **Data availability statement**

- 626 The dataset generated and analyzed for the current study are available to academic researchers 627 with a Data Use Agreement with MGH and Aromha, Inc.
- 628
- 629 **References**
- 630 1. 2023 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* **19**, 1598–1695 (2023).
- 631 2. Jack, C. R. *et al.* Longitudinal tau PET in ageing and Alzheimer's disease. *Brain* **141**, 1517–

# 632 1528 (2018).

- 633 3. Bateman, R. J. *et al.* Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's
- 634 Disease. *n engl j med* 10 (2012).
- 635 4. Villemagne, V. L. *et al.* Amyloid β deposition, neurodegeneration, and cognitive decline in
- 636 sporadic Alzheimer's disease: a prospective cohort study. **12**, 11 (2013).
- 637 5. Jia, J. *et al.* Biomarker Changes during 20 Years Preceding Alzheimer's Disease. *N Engl J*
- 638 *Med* **390**, 712–722 (2024).
- 639 6. Munro, C. E. *et al.* Recent contributions to the field of subjective cognitive decline in aging: A
- 640 literature review. *Alz & Dem Diag Ass & Dis Mo* **15**, e12475 (2023).
- 641 7. Knopman, D. S. *et al.* Alzheimer disease. *Nat Rev Dis Primers* **7**, 33 (2021).

- 642 8. Cummings, J., Feldman, H. H. & Scheltens, P. The "rights" of precision drug development for
- 643 Alzheimer's disease. *Alz Res Therapy* **11**, 76 (2019).
- 644 9. Sperling, R. A., Jack, C. R. & Aisen, P. S. Testing the Right Target and Right Drug at the
- 645 Right Stage. *Sci. Transl. Med.* **3**, (2011).
- 646 10. Kim, C. K. *et al.* Alzheimer's disease: key insights from two decades of clinical trial
- 647 failures. *Journal of Alzheimer's Disease* **87**, 83–100 (2022).
- 648 11. Cummings, J. *et al.* Re-engineering Alzheimer clinical trials: Global Alzheimer's Platform 649 network. *The journal of prevention of Alzheimer's disease* **3**, 114 (2016).
- 650 12. Reiss, A. B. *et al.* Alzheimer's disease: many failed trials, so where do we go from here?
- 651 *Journal of Investigative medicine* **68**, 1135–1140 (2020).
- 652 13. Murphy, C. Olfactory and other sensory impairments in Alzheimer disease. *Nat Rev*  653 *Neurol* **15**, 11–24 (2019).
- 654 14. Albers, M. W., Tabert, M. H. & Devanand, D. P. Olfactory dysfunction as a predictor of 655 neurodegenerative disease. *Curr Neurol Neurosci Rep* **6**, 379–386 (2006).
- 656 15. Pashkovski, S. L. *et al.* Structure and flexibility in cortical representations of odour 657 space. *Nature* **583**, 253–258 (2020).
- 658 16. Sosulski, D. L., Bloom, M. L., Cutforth, T., Axel, R. & Datta, S. R. Distinct
- 659 representations of olfactory information in different cortical centres. *Nature* **472**, 213–216 660 (2011).
- 661 17. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. *Acta*  662 *Neuropathol* **82**, 239–259 (1991).
- 663 18. Diez, I. *et al.* Tau propagation in the brain olfactory circuits is associated with smell 664 perception changes in aging. *Nat Commun* **15**, 4809 (2024).
- 665 19. Arnold, S. E. *et al.* Olfactory epithelium amyloid-β and paired helical filament-tau
- 666 pathology in Alzheimer disease. *Ann Neurol.* **67**, 462–469 (2010).

- 667 20. Jobin, B., Boller, B. & Frasnelli, J. Volumetry of Olfactory Structures in Mild Cognitive
- 668 Impairment and Alzheimer's Disease: A Systematic Review and a Meta-Analysis. *Brain*

669 *Sciences* **11**, 1010 (2021).

- 670 21. Jobin, B., Boller, B. & Frasnelli, J. Smaller grey matter volume in the central olfactory 671 system in mild cognitive impairment. *Experimental Gerontology* (2023).
- 672 22. Lu *et al.* Functional Connectivity between the Resting-State Olfactory Network and the
- 673 Hippocampus in Alzheimer's Disease. *Brain Sciences* **9**, 338 (2019).
- 674 23. Vasavada, M. M. *et al.* Olfactory cortex degeneration in Alzheimer's disease and mild 675 cognitive impairment. *Journal of Alzheimer's disease* **45**, 947–958 (2015).
- 676 24. Doty, R. L., Shaman, P., Kimmelman, C. P. & Dann, M. S. University of Pennsylvania
- 677 Smell Identification Test: a rapid quantitative olfactory function test for the clinic. *The*
- 678 *Laryngoscope* **94**, 176–178 (1984).
- 679 25. Hummel, T., Sekinger, B., Wolf, S. R., Pauli, E. & Kobal, G. 'Sniffin'sticks': olfactory
- 680 performance assessed by the combined testing of odor identification, odor discrimination and
- 681 olfactory threshold. *Chemical senses* **22**, 39–52 (1997).
- 682 26. Lafaille-Magnan, M.-E. *et al.* Odor identification as a biomarker of preclinical AD in older 683 adults at risk. *Neurology* **89**, 327–335 (2017).
- 684 27. Risacher, S. L. *et al.* Olfactory identification in subjective cognitive decline and mild
- 685 cognitive impairment: Association with tau but not amyloid positron emission tomography.
- 686 *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* **9**, 57–66 (2017).
- 687 28. Tu, L. *et al.* Association of Odor Identification Ability With Amyloid-β and Tau Burden: A
- 688 Systematic Review and Meta-Analysis. *Front. Neurosci.* **14**, 586330 (2020).
- 689 29. Klein, J. *et al.* Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation 690 in Alzheimer's Disease. *JAD* **80**, 1051–1065 (2021).
- 691 30. Reijs, B. L. R. *et al.* Relation of Odor Identification with Alzheimer's Disease Markers in
- 692 Cerebrospinal Fluid and Cognition. *JAD* **60**, 1025–1034 (2017).

- 693 31. Devanand, D. P. *et al.* Olfactory identification deficits and MCI in a multi-ethnic elderly
- 694 community sample. *Neurobiology of Aging* **31**, 1593–1600 (2010).
- 695 32. Kose, Y. *et al.* Association between the inability to identify particular odors and physical
- 696 performance, cognitive function, and/or brain atrophy in community-dwelling older adults from
- 697 the Fukuoka Island City study. *BMC Geriatr* **21**, 421 (2021).
- 698 33. Hagemeier, J. *et al.* Odor identification deficit in mild cognitive impairment and
- 699 Alzheimer's disease is associated with hippocampal and deep gray matter atrophy.
- 700 *Psychiatry Research: Neuroimaging* **255**, 87–93 (2016).
- 701 34. Kjelvik, G. *et al.* The brain structural and cognitive basis of odor identification deficits in
- 702 mild cognitive impairment and Alzheimer's disease. *BMC Neurol* **14**, 168 (2014).
- 703 35. Murphy, C., Jernigan, T. L. & Fennema-Notestine, C. Left hippocampal volume loss in
- 704 Alzheimer's disease is reflected in performance on odor identification: A structural MRI study.
- 705 *J Int Neuropsychol Soc* **9**, 459–471 (2003).
- 706 36. Yoshii, F., Onaka, H., Kohara, S., Ryo, M. & Takahashi, W. Association of Smell
- 707 Identification Deficit with Alzheimer's Disease Assessment Scale-Cognitive Subscale,
- 708 Japanese Version Scores and Brain Atrophy in Patients with Dementia. *Eur Neurol* **81**, 145– 709 151 (2019).
- 710 37. Yu, H., Chen, Z., Zhao, J., Duan, S. & Zhao, J. Olfactory Impairment and Hippocampal
- 711 Volume in a Chinese MCI Clinical Sample. *Alzheimer Disease & Associated Disorders* **33**, 712 124–128 (2019).
- 713 38. Jobin, B., Roy-Côté, F., Frasnelli, J. & Boller, B. Olfaction and Declarative Memory in
- 714 Aging: A Meta-analysis. *Chemical Senses* bjad045 (2023) doi:10.1093/chemse/bjad045.
- 715 39. Tabert, M. H. *et al.* A 10-item smell identification scale related to risk for Alzheimer's 716 disease. *Ann Neurol.* **58**, 155–160 (2005).
- 717 40. Devanand, D. P. *et al.* Combining Early Markers Strongly Predicts Conversion from Mild
- 718 Cognitive Impairment to Alzheimer's Disease. *Biological Psychiatry* **64**, 871–879 (2008).

- 719 41. Conti, M. Z. *et al.* Odor Identification Deficit Predicts Clinical Conversion from Mild 720 Cognitive Impairment to Dementia Due to Alzheimer's Disease. *Archives of Clinical*  721 *Neuropsychology* **28**, 391–399 (2013).
- 722 42. Roberts, R. O. *et al.* Association between olfactory dysfunction and amnestic mild
- 723 cognitive impairment and Alzheimer disease dementia. *JAMA neurology* **73**, 93–101 (2016).
- 724 43. Dhilla Albers, A. *et al.* Episodic memory of odors stratifies Alzheimer biomarkers in
- 725 normal elderly: POEM: Odor Memory Biomarker in Normal Elderly. *Ann Neurol.* **80**, 846–857 726 (2016).
- 727 44. Devanand, D. P. *et al.* Olfactory deficits predict cognitive decline and Alzheimer
- 728 dementia in an urban community. *Neurology* **84**, 182–189 (2015).
- 729 45. Dintica, C. S. *et al.* Impaired olfaction is associated with cognitive decline and
- 730 neurodegeneration in the brain. *Neurology* **92**, e700–e709 (2019).
- 731 46. Growdon, M. E. *et al.* Odor identification and Alzheimer disease biomarkers in clinically 732 normal elderly. *Neurology* **84**, 2153–2160 (2015).
- 733 47. Olofsson, J. K., Larsson, M., Roa, C., Wilson, D. A. & Jonsson Laukka, E. Interaction
- 734 Between Odor Identification Deficit and APOE4 Predicts 6-Year Cognitive Decline in Elderly
- 735 Individuals. *Behav Genet* **50**, 3–13 (2020).
- 736 48. Sohrabi, H. R. *et al.* Olfactory discrimination predicts cognitive decline among 737 community-dwelling older adults. *Transl Psychiatry* **2**, e118–e118 (2012).
- 738 49. Windon, M. J., Kim, S. J., Oh, E. S. & Lin, S. Y. Predictive value of olfactory impairment
- 739 for cognitive decline among cognitively normal adults. *The Laryngoscope* **130**, 840–847 740 (2019).
- 741 50. Wheeler, P. L. & Murphy, C. Olfactory Measures as Predictors of Conversion to Mild 742 Cognitive Impairment and Alzheimer's Disease. *Brain Sciences* **11**, 1391 (2021).
- 743 51. Wilson, R. S. *et al.* Olfactory Identification and Incidence of Mild Cognitive Impairment in
- 744 Older Age. *Arch Gen Psychiatry* **64**, 802 (2007).

- 745 52. Rahayel, S., Frasnelli, J. & Joubert, S. The effect of Alzheimer's disease and
- 746 Parkinson's disease on olfaction: A meta-analysis. *Behavioural Brain Research* **231**, 60–74 747 (2012).
- 748 53. Schofield, P. W., Moore, T. M. & Gardner, A. Traumatic Brain Injury and Olfaction: A 749 Systematic Review. *Front. Neurol.* **5**, (2014).
- 750 54. Audronyte, E., Pakulaite-Kazliene, G., Sutnikiene, V. & Kaubrys, G. Odor Discrimination
- 751 as a Marker of Early Alzheimer's Disease. *JAD* 1–10 (2023) doi:10.3233/JAD-230077.
- 752 55. Bastin, C. *et al.* Anosognosia in Mild Cognitive Impairment: Lack of Awareness of
- 753 Memory Difficulties Characterizes Prodromal Alzheimer's Disease. *Front. Psychiatry* **12**,
- 754 631518 (2021).
- 755 56. Gallo, D. A., Cramer, S. J., Wong, J. T. & Bennett, D. A. Alzheimer's disease can spare
- 756 local metacognition despite global anosognosia: Revisiting the confidence–accuracy

757 relationship in episodic memory. *Neuropsychologia* **50**, 2356–2364 (2012).

- 758 57. Cosentino, S., Metcalfe, J., Butterfield, B. & Stern, Y. Objective Metamemory Testing
- 759 Captures Awareness of Deficit in Alzheimer's Disease. *Cortex* **43**, 1004–1019 (2007).
- 760 58. Vannini, P. *et al.* Decreased meta-memory is associated with early tauopathy in
- 761 cognitively unimpaired older adults. *NeuroImage: Clinical* **24**, 102097 (2019).
- 762 59. López-Martos, D. *et al.* Awareness of episodic memory and meta-cognitive profiles:
- 763 associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's
- 764 continuum. *Front. Aging Neurosci.* **16**, 1394460 (2024).
- 765 60. Albers, M. W. *et al.* At the interface of sensory and motor dysfunctions and Alzheimer's 766 disease. *Alzheimer's & Dementia* **11**, 70–98 (2015).
- 767 61. Patel, Z. M. *et al.* International consensus statement on allergy and rhinology: Olfaction. 768 *Int Forum Allergy Rhinol* **12**, 327–680 (2022).

- 769 62. Rodriguez, S. *et al.* Innate immune signaling in the olfactory epithelium reduces odorant
- 770 receptor levels: modeling transient smell loss in COVID-19 patients. Preprint at
- 771 https://doi.org/10.1101/2020.06.14.20131128 (2020).
- 772 63. Ergun, B. *et al.* Longitudinal Assessment Of Subjective And Objective Changes In
- 773 Olfactory Function Following Sars-Cov-2 Infection: A Focus On Odor Identification, Intensity,
- 774 And General Smell Function. in (Bonita Springs, FL, 2024).
- 775 64. Jobin, B. *et al.* Olfactory function is predictive of brain volumes and memory of former
- 776 professional football players in the Harvard Football Players Health Study. in (Reykjavík,
- 777 Iceland., 2024).
- 778 65. Runde, A. *et al.* Digital Accessible Remote Olfactory Mediated Health Assessments For 779 Preclinical AD. in (Bonita Springs, FL, 2024).
- 780 66. Jessen, F. *et al.* A conceptual framework for research on subjective cognitive decline in 781 preclinical Alzheimer's disease. *Alzheimer's & Dementia* **10**, 844–852 (2014).
- 782 67. Sperling, R. A. *et al.* Toward defining the preclinical stages of Alzheimer's disease:
- 783 Recommendations from the National Institute on Aging-Alzheimer's Association workgroups
- 784 on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia* **7**, 280–292 (2011).
- 785 68. Jonsson, F. U. Olfactory Metacognition. *Chemical Senses* **28**, 651–658 (2003).
- 786 69. Jonsson, F. U. Odor Emotionality Affects the Confidence in Odor Naming. *Chemical*  787 *Senses* **30**, 29–35 (2005).
- 788 70. Roalf, D. R. *et al.* A quantitative meta-analysis of olfactory dysfunction in mild cognitive 789 impairment. *J Neurol Neurosurg Psychiatry* **88**, 226–232 (2017).
- 790 71. Kjelvik, G. *et al.* The Human Brain Representation of Odor Identification in Amnestic Mild
- 791 Cognitive Impairment and Alzheimer's Dementia of Mild Degree. *Frontiers in Neurology* **11**,
- 792 1779 (2021).
- 793 72. Patin, A. & Pause, B. M. Human amygdala activations during nasal chemoreception.
- 794 *Neuropsychologia* **78**, 171–194 (2015).

- 795 73. Larsson, M. *et al.* Olfactory memory in the old and very old: relations to episodic and 796 semantic memory and APOE genotype. *Neurobiology of Aging* **38**, 118–126 (2016).
- 797 74. Martin, C., Beshel, J. & Kay, L. M. An Olfacto-Hippocampal Network Is Dynamically
- 798 Involved in Odor-Discrimination Learning. *Journal of Neurophysiology* **98**, 2196–2205 (2007).
- 799 75. Desiato, V. M. *et al.* The Prevalence of Olfactory Dysfunction in the General Population:
- 800 A Systematic Review and Meta-analysis. *Am J RhinolAllergy* **<sup>35</sup>**, 195–205 (2021).
- 801 76. Zhang, C. & Wang, X. Initiation of the age-related decline of odor identification in
- 802 humans: A meta-analysis. *Ageing Research Reviews* **40**, 45–50 (2017).
- 803 77. Oleszkiewicz, A., Schriever, V., Croy, I., Hähner, A. & Hummel, T. Updated Sniffin'Sticks
- 804 normative data based on an extended sample of 9139 subjects. *European Archives of Oto-*
- 805 *Rhino-Laryngology* **276**, 719–728 (2019).
- 806 78. Moberg, P. J. & Raz, N. Aging and Olfactory Recognition Memory: Effect of Encoding 807 Strategies and Cognitive Abilities. *International Journal of Neuroscience* **90**, 277–291 (1997).
- 808 79. Murphy, C., Nordin, S. & Acosta, L. Odor learning, recall, and recognition memory in
- 809 young and elderly adults. *Neuropsychology* **11**, 126 (1997).
- 810 80. Rovee, C. K., Cohen, R. Y. & Schlapack, W. Life-span stability in olfactory sensitivity. 811 *Developmental Psychology* **11**, 311 (1975).
- 812 81. Cowart, B. J. Relationships between taste and smell across the adult life span a. *Annals*  813 *of the New York academy of Sciences* **561**, 39–55 (1989).
- 814 82. Murphy, C. Age-related effects on the threshold, psychophysical function, and 815 pleasantness of menthol. *Journal of Gerontology* **38**, 217–222 (1983).
- 816 83. Frasnelli, J. *et al.* Neuroanatomical correlates of olfactory performance. *Exp Brain Res* 817 **201**, 1–11 (2010).
- 818 84. Savic, I., Gulyas, B., Larsson, M. & Roland, P. Olfactory Functions Are Mediated by
- 819 Parallel and Hierarchical Processing. *Neuron* **26**, 735–745 (2000).

- 820 85. Wilson, D. A. *et al.* Cortical Odor Processing in Health and Disease. in *Progress in Brain*  821 *Research* vol. 208 275–305 (Elsevier, 2014).
- 822 86. Haehner, A., Hummel, T. & Reichmann, H. Olfactory Loss in Parkinson′s Disease.
- 823 *Parkinson's Disease* **2011**, 450939 (2011).
- 824 87. Yoo, H. S. *et al.* Olfactory dysfunction in Alzheimer's disease– and Lewy body–related 825 cognitive impairment. *Alzheimer's &amp*; Dementia **14**, 1243–1252 (2018).
- 826 88. Carnemolla, S. E. *et al.* Olfactory dysfunction in frontotemporal dementia and psychiatric 827 disorders: A systematic review. *Neuroscience & Biobehavioral Reviews* **118**, 588–611
- 828 (2020).
- 829 89. Lecuyer Giguere, F. *et al.* Early Parosmia Signs and Affective States Predict Depression
- 830 and Anxiety Symptoms 6 Months After a Mild Traumatic Brain Injury. *Chemical Senses* **45**,
- 831 483–490 (2020).
- 832 90. Alosco, M. L. *et al.* Olfactory Function and Associated Clinical Correlates in Former

833 National Football League Players. *Journal of Neurotrauma* **34**, 772–780 (2017).

- 834 91. Zigrand, C. *et al.* Olfactory perception in patients with a mild traumatic brain injury: a 835 longitudinal study. *Brain Injury* **36**, 985–990 (2022).
- 836 92. Doraiswamy, P. M., Narayan, V. A. & Manji, H. K. Mobile and pervasive computing
- 837 technologies and the future of Alzheimer's clinical trials. *Npj Digital Medicine* **1**, 1 (2018).

838 93. Kaye, J. *et al.* Using digital tools to advance Alzheimer's drug trials during a pandemic:

- 839 the EU/US CTAD task force. *The journal of prevention of Alzheimer's disease* **8**, 513–519 840 (2021).
- 841 94. Green, P., Rohling, M. L., Iverson, G. L. & Gervais, R. O. Relationships between 842 olfactory discrimination and head injury severity. *Brain Injury* **17**, 479–496 (2003).
- 843 95. Tsai, M. S. *et al.* Apolipoprotein E: risk factor for Alzheimer disease. *Am J Hum Genet*
- 844 **54**, 643–649 (1994).

- 845 96. Weiner, M. W. *et al.* Increasing participant diversity in AD research: plans for digital
- 846 screening, blood testing, and a community-engaged approach in the Alzheimer's Disease<br>847 Neuroimaging Initiative 4. *Alzheimer's & Dementia* 1<mark>9</mark>, 307–317 (2023).
- 847 Neuroimaging Initiative 4. *Alzheimer's & Dementia* **19**, 307–317 (2023).
- 848 97. Kruse, C. S. *et al.* Telehealth and patient satisfaction: a systematic review and narrative
- 849 analysis. *BMJ Open* **7**, e016242 (2017).
- 850 98. Atmojo, J. T. *et al.* Telemedicine, Cost Effectiveness, and Patients Satisfaction: A
- 851 Systematic Review. *J HEALTH POLICY MANAGE* **5**, 103–107 (2020).
- 852 99. Albert, M. S. *et al.* The diagnosis of mild cognitive impairment due to Alzheimer's
- 853 disease: Recommendations from the National Institute on Aging-Alzheimer's Association
- 854 workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia* **7**,
- 855 270–279 (2011).
- 856

#### 857 **Figure legends.**

858 **Figure 1. AROMHA Brain Health Test.** Following online prescreening, online consent, the

859 web-based program instructs you through the 5 bilingual (English / Spanish) cards (A). Card A is

860 comprised of a practice odor P followed by the 9 odor labels comprising the OPID9 test.

861 Adjacent in the blue box (B) is the workflow for these tests as directed by

862 the testyourbrainhealth.com software to generate the OPID9, OPID9noguess, and average

863 intensity scores. After a 10-minute break, participants are instructed to work through Cards B

864 and C using the workflow in the green box (B) to generate the POEM, OPID18, and

865 OPID18noguess scores. Then participants are instructed to move on to Cards D and E using the

866 workflow in the purple box (B) to generate an OD10 odor discrimination score.

867

#### 868 **Figure 2. Linear regression model between olfactory scores and age across CN participants.**

- 869 Greater age was significantly associated with lower (b) OPID9noguess  $(\beta = -0.02, SE = .007, p = 0.02)$
- 870 .002, adj.  $R^2 = .06$ ), (c) OPID18 ( $\beta = -0.04$ ,  $SE = 0.001$ ,  $p < .001$ , adj.  $R^2 = .12$ ), (d)
- 871 OPID18noguess (β = -0.06, SE = 0.03, p < .001, adj.  $R^2 = .13$ ), (e) OD10 (β = -0.02, SE =
- *0.005, p < .001, adj.*  $R^2 = .16$ , and (f) POEM ( $\beta = -0.004$ ,  $SE = 0.001$ , p < .001, adj.  $R^2 = .08$ )

scores, while the association with (a) OPID9 ( $\beta$  = -0.01, SE = 0.005 p = .01, adj.  $R^2$  = .04) and 874 (f) average intensity ( $\beta = -0.007$ ,  $SE = 0.007$ ,  $p = .28$ , *adj.*  $R^2 = .001$ ) scores did not reach significance after Bonferroni correction for 21 comparisons (*p* < .002).

**Table legends.** 

#### **Table 1. Demographic information and olfactory function in cognitively normal**

**participants who underwent observed and unobserved self-administration conditions of the** 

**AROMHA Brain Health Test.** Values are means (SD). T-tests were performed across groups for age, education, olfactory scores, and test duration. Chi-square test was performed on sex and speaking-language proportions across groups. **Bold** indicates a statistically significant difference

that remained significant after Bonferroni correction.

### **Table 2. Distribution of olfactory scores of anosmic patients and CN participants on the**

**AROMHA Brain Health Test.** The first column lists the score following random selection of 887 the answers for each test, e.g., the participant had no olfactory information to guide selection of 888 the answers. Values are means (SD).  $NA = not$  applicable. Wilcoxon signed-rank tests were 889 performed across groups for age, education, olfactory scores, and test duration. The chi-square test was performed for sex. **Bold** indicates a statistically significant difference that remained significant after Bonferroni correction.

**Table 3. Demographic information and olfactory function in cognitively normal English-**

**speaking and Spanish-speaking participants.** Values are means (SD). T-tests were performed across groups for age, education, clinical variables, olfactory scores, and test duration. Chi-square test was performed on sex and speaking-language proportions across groups. **Bold** indicates a statistically significant difference that remained significant after Bonferroni correction.

**Table 4. Olfactory function across cognitive status among participants aged 55+.** Values are

means (SD). T-tests were performed across groups for age, education, clinical variables,

olfactory scores, and test duration. Chi-square test was performed on sex proportion across

- 903 groups. **Bold** indicates a statistically significant difference that remained significant after
- 904 Bonferroni correction for 21 comparisons ( $p < .002$ ).
- 905

# 906 **Table 5. ANCOVA models comparing different olfactory scores across groups.** DF =

- 907 Degrees of Freedom,  $F = F$ -statistic,  $p = p$ -value,  $np^2 =$ partial Eta squared. CI = Confidence
- 908 interval. **Bold** represents post-hoc *p* values that remained significant after Bonferroni correction
- 909 for 21 comparisons ( $p < .002$ ). <sup>a</sup> p values from pairwise post-hoc comparisons adjusted for age,
- 910 sex, and education.